Sunday, April 23, 2017 6:19:40 AM
"So the above incorrectly states that a PIPE would be a suitable replacement for Anavex's current agreement with LPC... but Missling as put an ATM in place which is more favorable than a PIPE. "
Let's begin with the concept that a PIPE and an "ATM" ( which you apparently still believe is the correct term for the LPC agreement) are not mutually exclusive and can both be used simultaneously.
Here is an example of a PIPE which occurred with another company who has an ELOC ( what I believe is the correct term) in place simultaneously.
"We are offering 2,471,912 shares of our Class A common stock, par value $0.0001 per share, which we refer to as our common stock, directly to the investors in this offering at a price of $0.89 per share. "
https://www.sec.gov/Archives/edgar/data/1355250/000147793217001372/ctix_424b5.htm
Secondly, you should notice that I asked for an "opinion" on the possibility of Anavex planning to utilize the proposed preferred stock (that failed to pass) as a PIPE rather than suggesting it was a "preferable" method.
Third, I believe the correct term for the LPC agreement is an ELOC and in a previous post I even provided you a link to an SEC document from another company that described an LPC agreement as an ELOC.
Please read the following link and see if an ELOC is a different thing than you believe it to be.
http://www.ascendiant.com/upload/Equitylinesarticle.pdf
"First, an interesting point of clarification about the term “Equity Line”. Within the securities industry, the Equity Line has been known for years as an “Equity Line of Credit”, however, that is a confusing misnomer as there is no “credit” involved and the Equity Line is not a debt instrument. Unlike debt, an Equity Line does not charge interest and the funds received through the Equity Line do not have to be repaid. However, much like a traditional line of credit provided by a bank or asset-based lender allows a company to carry accounts receivable and inventory, an Equity Line allows a public company to “draw” against its equity on a periodic basis by selling registered shares of common stock to an investor for cash. For this reason, just as every company should consider a bank line of credit to support its operations and working capital needs, every public company should consider an Equity Line as a potential source of funding that can be accessed if and when needed."
Lastly, Consider the "possibility" that Anavex might want to has $50 million in the bank before they start the Phase 2/3 for Alzheimer's. With the current LPC agreement, the process will be slower, as they trickle the shares to LPC. If the "blank check preferred stock" had passed, they "could" have been planning to use those to accomplish the raise in one fell swoop.
Every form of financing has some sort of drawback, so I don't claim to have the answers about which works best with each situation. That's why I asked for an opinion rather than stating a preference.
Of note, even though PIPE's are at a discount to market, which is undesirable, sometimes the share price rebounds quickly as investors realize that the company now has the ability to move ahead with trials quickly.
Are you still of the opinion that Anavex should not consider it as a possible financing method?
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM